Skip to main content

Glucagon-Like Peptide-1 Receptor Agonists & Intentional Self-Harm

Basic Details
Status
Ongoing
Last Updated
Monday, July 22, 2024
Original Posting Date
Health Outcome(s)
intentional self-harm
Purpose
Drug and Outcome Analysis
Meets requirements of FD&C Act Sec 505(o) prior to requiring a PMR
No
Analytic Code Link(s) (2)
Sentinel Analytic Package: Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Obesity: A Descriptive Analysis Sentinel Analytic Package: Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Diabetes: An Inverse Probability of Treatment Weighting Analysis
Regulatory Link(s) (1)
FDA Safety Communication: Update on FDA's Ongoing Evaluation of Reports of Suicidal Thoughts or Actions in Patients Taking a Certain Type of Medicines Approved for Type 2 Diabetes and Obesity